Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine

D. Thomas; A. S. Gallus; P. M. Brooks; R. Tampi; R. Geddes; W. Hill

doi:10.1136/ard.43.3.402

Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine

D. Thomas, A. S. Gallus, P. M. Brooks, R. Tampi, R. Geddes, W. Hill

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

The mechanism of D-penicillamine induced thrombocytopenia in rheumatoid arthritis was investigated by measuring platelet life-span and platelet production rate in 2 groups of rheumatoid arthritis patients treated with 250-750 mg/day D-penicillamine, 14 with a normal platelet count and 9 with thrombocytopenia (platelet count 50-130 x 10⁹/l). Age matched control patients not treated with D-penicillamine included 14 with rheumatoid arthritis and 9 with osteoarthritis. The platelet life-span was normal, but platelet production rate was significantly reduced in the thrombocytopenic patients, suggesting that D-penicillamine causes thrombocytopenia through bone marrow suppression.

Original language	English
Pages (from-to)	402-406
Number of pages	5
Journal	Annals of the Rheumatic Diseases
Volume	43
Issue number	3
DOIs	https://doi.org/10.1136/ard.43.3.402
Publication status	Published - 1984

Access to Document

10.1136/ard.43.3.402Licence: In Copyright

Cite this

@article{bb22cc128c73427d95ecc21495b282f5,

title = "Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine",

abstract = "The mechanism of D-penicillamine induced thrombocytopenia in rheumatoid arthritis was investigated by measuring platelet life-span and platelet production rate in 2 groups of rheumatoid arthritis patients treated with 250-750 mg/day D-penicillamine, 14 with a normal platelet count and 9 with thrombocytopenia (platelet count 50-130 x 109/l). Age matched control patients not treated with D-penicillamine included 14 with rheumatoid arthritis and 9 with osteoarthritis. The platelet life-span was normal, but platelet production rate was significantly reduced in the thrombocytopenic patients, suggesting that D-penicillamine causes thrombocytopenia through bone marrow suppression.",

author = "D. Thomas and Gallus, {A. S.} and Brooks, {P. M.} and R. Tampi and R. Geddes and W. Hill",

year = "1984",

doi = "10.1136/ard.43.3.402",

language = "English",

volume = "43",

pages = "402--406",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier B.V.",

number = "3",

}

TY - JOUR

T1 - Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine

AU - Thomas, D.

AU - Gallus, A. S.

AU - Brooks, P. M.

AU - Tampi, R.

AU - Geddes, R.

AU - Hill, W.

PY - 1984

Y1 - 1984

N2 - The mechanism of D-penicillamine induced thrombocytopenia in rheumatoid arthritis was investigated by measuring platelet life-span and platelet production rate in 2 groups of rheumatoid arthritis patients treated with 250-750 mg/day D-penicillamine, 14 with a normal platelet count and 9 with thrombocytopenia (platelet count 50-130 x 109/l). Age matched control patients not treated with D-penicillamine included 14 with rheumatoid arthritis and 9 with osteoarthritis. The platelet life-span was normal, but platelet production rate was significantly reduced in the thrombocytopenic patients, suggesting that D-penicillamine causes thrombocytopenia through bone marrow suppression.

AB - The mechanism of D-penicillamine induced thrombocytopenia in rheumatoid arthritis was investigated by measuring platelet life-span and platelet production rate in 2 groups of rheumatoid arthritis patients treated with 250-750 mg/day D-penicillamine, 14 with a normal platelet count and 9 with thrombocytopenia (platelet count 50-130 x 109/l). Age matched control patients not treated with D-penicillamine included 14 with rheumatoid arthritis and 9 with osteoarthritis. The platelet life-span was normal, but platelet production rate was significantly reduced in the thrombocytopenic patients, suggesting that D-penicillamine causes thrombocytopenia through bone marrow suppression.

UR - http://www.scopus.com/inward/record.url?scp=0021187277&partnerID=8YFLogxK

U2 - 10.1136/ard.43.3.402

DO - 10.1136/ard.43.3.402

M3 - Article

AN - SCOPUS:0021187277

SN - 0003-4967

VL - 43

SP - 402

EP - 406

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 3

ER -

Thrombokinetics in patients with rheumatoid arthritis treated with D-penicillamine

Abstract

Access to Document

Other files and links

Fingerprint

Cite this